9 results about "Multimerin" patented technology

The invention discloses a polymer protein nanoparticle and application thereof in preparation of a novel coronavirus broad-spectrum vaccine, and the polymer protein nanoparticle is prepared by forming a pentamer compound FP-HR5 fusion protein by using heptapeptide repeat regions HR1 and HR2 and a fusion peptide FP on a coronavirus S protein, and on the basis, assembling with Ferritin to obtain the polymer protein nanoparticle. And preparing the novel coronavirus antigen polymer compound FP-HR5-NP protein nanoparticles. The novel coronavirus universal nanoparticle vaccine which can be inoculated through injection or a respiratory system and has a good immune protection effect is prepared by taking the coronavirus as an immunogen. The obtained novel coronavirus vaccine is good in immune protection effect, mucosal immunity can be remarkably activated after a respiratory system is inoculated, infection of novel coronaviruses of different mutant strains can be avoided after the respiratory system is inoculated, the preparation method is simple, the protein expression and purification technical route is mature, safety is high, and the novel coronavirus vaccine can be rapidly applied to clinical tests.

The present invention relates to heterologous polypeptide or multimeric proteins and nucleic acids encoding the same comprising at least one immunoglobulin binding domain and at least one immune cell surface polypeptide or protein binding domain. The molecules of the invention can be used as monotherapy or for enhancing standard, current or experimental antibody-based immunotherapy, such as cancer, autoimmunity or pathogenic infections.

Provided is a novel production method with which it is possible to produce a heteromultimeric protein such as a bispecific antibody. A method for producing a heteromultimeric protein according to the present invention comprises: a complex formation step for forming a first complex of the two proteins by bringing the two proteins into contact with each other, the two proteins comprising a first protein and a second protein, the first protein comprises a first binding tag, a first cleavage domain, and a first domain in this order from the N-terminal to the C-terminal, and the second protein comprises a first binding partner capable of binding to the first binding tag, a second cleavage domain, and a second domain in this order from the N-terminal to the C-terminal. The first protein and the second protein are capable of forming a dimer by means of the binding between the first domain and the second domain, the first protein and the second protein are bound to the first binding partner by means of the first binding tag, and the first domain is bound to the second domain to form the first complex; and a generation step in which the first cleaved domain and the second cleaved domain in the first complex are cleaved to generate a heterodimer of the first domain and the second domain.

Described herein are methods for the efficient production of antibodies and other multimeric protein complexes (collectively referred to herein as heteromultimeric proteins) capable of specifically binding to more than one target. The targets may be, for example, different epitopes located on a single molecule or on different molecules.

The present invention relates to heterologous polypeptides or multimeric proteins, and nucleic acids encoding the same, comprising at least one immunoglobulin-binding domain and at least immune cell surface polypeptide or protein binding domain. Molecules of the invention can be used as a monotherapy or used to enhance standard, current or experimental antibody-based immunotherapy, such as cancer, autoimmunity or pathogenic infections.

To provide variants of OB-fold proteins, in particular of the Sac7d family, that are able to bind a subunit of a multimeric protein and inhibit the formation of the multimer.SOLUTION: The present invention provides a polypeptide comprising a variant of a protein of the Sac7d family, the variant comprising 4 to 22 mutated amino acids in the binding site of the protein of the Sac7d family, that binds to a subunit of a multimeric protein and that does not bind to the subunit of the protein when such subunit protein is involved in the fully formed multimeric protein in its native state.SELECTED DRAWING: None

The present invention relates to viral vectors co-encoding an artificial CD4 T cell epitope (PADRE) for enhanced immune responses to encoded multimeric protein particle displayed vaccine antigens.

The invention relates generally to polypeptides comprising a lectin domain, multimeric proteins comprising the polypeptides, and use of the polypeptides or multimeric proteins in the detection of a carbohydrate (e.g., a sialic acid containing carbohydrate or Siglec ligand) or the treatment of a Siglec-mediated disorder.

Disclosed herein are compounds and compositions thereof which find use in increasing stability of TTR tetramers reducing its tendency to misfold and form aggregates. Also provided herein are methods for using these compounds and compositions for increasing stability of TTR and thereby decreasing aggregate formation by TTR. Also disclosed herein are methods to screen for candidate compounds that increase stability of TTR. Also disclosed herein are heterobifunctional compounds that include a TTR binding compound connected to a targeting moiety via a linker, for use in disrupting PPIs of a target protein.